A Randomized, Open-label, Active-controlled, Multi-center, Phase III Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy
Phase of Trial: Phase III
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Filgrastim (Primary)
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Dong-A ST
- 13 Dec 2018 Planned End Date changed from 31 Oct 2018 to 31 Aug 2019.
- 13 Dec 2018 Planned primary completion date changed from 31 Aug 2018 to 31 Dec 2018.
- 21 Nov 2017 New trial record